Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes

NCT01154543 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2013-03-20

No results posted yet for this study

Summary

To determine the efficacy of Famvir 500mg bd as suppressive antiviral therapy for acute genital Herpes simplex virus (HSV) outbreaks in HIV subjects.

Conditions

  • HIV Positive
  • Herpes Simplex, Genital

Sponsors & Collaborators

  • Holdsworth House Medical Practice

    lead OTHER

Principal Investigators

  • Mark T Bloch, MBBS · Australian Health Practitioners Regulation authority

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2013-01-31
Completion
2013-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154543 on ClinicalTrials.gov